Medical Cannabis for Nausea and Appetite: Current Research

Understanding the Research

This summary brings together recent peer-reviewed research from PubMed, the database of the U.S. National Library of Medicine. The goal is to share what current studies show regarding cannabis and its related compounds in relation to nausea, appetite, and digestive health. Please note: this information is for educational purposes only and is not medical advice.

What the Studies Show

Medical cannabis use is widespread. A review in JAMA reports that roughly 27% of adults in the U.S. and Canada have used cannabis medicinally, with about 10.5% of the U.S. population using CBD—a non-psychoactive compound. The FDA has approved cannabinoids for specific conditions, including nausea and vomiting caused by chemotherapy, appetite loss related to HIV/AIDS, and certain seizure disorders.

A 2025 overview in Phytotherapy Research confirms that the use of cannabis-derived products has grown rapidly, leading to a large volume of systematic reviews on the benefits and harms across various health conditions.

Nausea and Digestive Outcomes

For patients facing chemotherapy-related nausea, a pilot trial in Biomedicines looked at cannabis oil as a potential intervention while monitoring gut-immune markers like short-chain fatty acids (SCFA). The trial was a small, double-blind, placebo-controlled study with six participants in the cannabis group.

Conversely, a study in Surgical Endoscopy examined cannabis use before surgery for gastroparesis. The researchers found that cannabis has been associated with delayed gastric emptying, which may worsen symptoms for some patients. While its impact on outcomes after surgical treatment was still uncertain in that specific study, it highlights how cannabis can affect the digestive system differently depending on the condition.Chronic Pain and Evidence Gaps

A systematic review in Annals of Internal Medicine found that the benefits and harms of cannabinoids for chronic pain remain uncertain. The researchers reviewed a wide range of studies, categorizing products by their THC-to-CBD ratio and the source of the extract, concluding that more evidence is still needed.Summary and Next Steps

The research shows that while cannabis and CBD are widely used and have specific FDA approvals for chemotherapy-induced nausea and appetite loss, outcomes vary by condition and product type. For example, it may be linked to delayed gastric emptying in some cases, while other studies are still exploring how it interacts with gut immunity during chemotherapy.Because this research is still evolving and every patient is different, the best way to understand what these findings mean for your health is to talk with a licensed physician. They can help you weigh the evidence against your specific medical history.